Trade KURA anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Kura Oncology, Inc. (KURA) is trading at US$13.25, up 0.76% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$1.06B. Over the past 52 weeks, KURA has traded between US$7.36 and US$13.90. On Syfe you can trade KURA with $0 commission and add it to your watchlist.
| Previous close | US$13.15 |
|---|---|
| Market cap | US$1.06B |
| 52-week range | US$7.36 – US$13.90 |
| Volume | 1.31M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Kura Oncology, Inc.
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Year: 2015
Kura Oncology, Inc. (KURA) stock is trading at US$13.25, +0.76% from the previous close of US$13.15.
The market cap for Kura Oncology, Inc. (KURA) stock is approximately US$1.06B.
The 52-week high for Kura Oncology, Inc. (KURA) stock is US$13.90.
The 52-week low for Kura Oncology, Inc. (KURA) stock is US$7.36.
Kura Oncology, Inc. (KURA) does not currently pay a dividend.
Stay on top of KURA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
